GlobeNewswire: Novartis Pharma AG Contains the last 10 of 2831 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:35:22ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/22/2850884/0/en/Novartis-Fabhalta-iptacopan-receives-positive-CHMP-opinion-as-first-oral-monotherapy-for-adult-patients-with-paroxysmal-nocturnal-hemoglobinuria-PNH.html?f=22&fvtc=4&fvtv=30456Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)2024-03-22T11:22:13Z<![CDATA[Basel, March 22, 2024 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for Fabhalta® (iptacopan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia1.]]>https://www.globenewswire.com/news-release/2024/03/05/2840564/0/en/Novartis-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Annual-General-Meeting.html?f=22&fvtc=4&fvtv=30456Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting2024-03-05T14:22:17Z<![CDATA[Basel, March 5, 2024 – Novartis shareholders today agreed to the Board of Directors’ recommendations for all proposed resolutions at the company’s Annual General Meeting (AGM). A total of 1693 shareholders were present at the meeting held in Basel, representing approximately 53.65% of the issued shares of Novartis.]]>https://www.globenewswire.com/news-release/2024/03/05/2840564/0/fr/Les-actionnaires-de-Novartis-approuvent-toutes-les-r%C3%A9solutions-propos%C3%A9es-par-le-Conseil-d-administration-lors-de-l-Assembl%C3%A9e-g%C3%A9n%C3%A9rale-ordinaire.html?f=22&fvtc=4&fvtv=30456Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire2024-03-05T14:22:17Z<![CDATA[Bâle, 5 mars 2024 — Les actionnaires de Novartis ont accepté aujourd’hui les recommandations du Conseil d’administration pour toutes les résolutions proposées lors de l’Assemblée générale ordinaire (AGO) de la société. Au total, 1693 actionnaires étaient présents à l’assemblée qui s’est tenue à Bâle, représentant ainsi environ 53,65% des actions de Novartis émises.]]>https://www.globenewswire.com/news-release/2024/03/05/2840564/0/de/Aktion%C3%A4rinnen-und-Aktion%C3%A4re-von-Novartis-heissen-an-der-ordentlichen-Generalversammlung-alle-Antr%C3%A4ge-des-Verwaltungsrats-gut.html?f=22&fvtc=4&fvtv=30456Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut2024-03-05T14:22:17Z<![CDATA[Basel, 5. März 2024 – Die Aktionärinnen und Aktionäre von Novartis stimmten heute den Empfehlungen des Verwaltungsrats für alle vorgeschlagenen Beschlüsse an der ordentlichen Generalversammlung (GV) des Unternehmens zu. Insgesamt waren 1693 Aktionärinnen und Aktionäre bei der in Basel abgehaltenen Versammlung anwesend, was rund 53.65% der ausgegebenen Aktien von Novartis entspricht.]]>https://www.globenewswire.com/news-release/2024/03/04/2839221/0/en/Novartis-presents-new-data-on-safety-and-efficacy-of-Zolgensma-including-maintained-and-improved-motor-milestones-in-older-and-heavier-children-with-SMA.html?f=22&fvtc=4&fvtv=30456Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA2024-03-04T06:15:00Z<![CDATA[Basel, March 4, 2024 – Novartis today presented new data that continue to support the clinical benefits of Zolgensma® (onasemnogene abeparvovec), the only one-time gene therapy for the treatment of spinal muscular atrophy (SMA). Final data from the SMART study highlight the safety and efficacy profile of Zolgensma in children with SMA weighing ≥ 8.5 kg to ≤ 21 kg, with a mean age of 4.69 years, most of whom (21/24, 87.5%) had discontinued use of another disease modifying therapy at the time of treatment. The new clinical results supplement emerging real-world experience and use of this innovative therapy in older and heavier children in countries where authorized use is not restricted by age. These data are among a Zolgensma data set being presented during the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Orlando, Florida, March 3 – 6.]]>https://www.globenewswire.com/news-release/2024/02/05/2823889/0/en/Novartis-to-strengthen-oncology-pipeline-with-agreement-to-acquire-MorphoSys-AG-for-EUR-68-per-share-or-an-aggregate-of-EUR-2-7bn-in-cash.html?f=22&fvtc=4&fvtv=30456Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash2024-02-05T21:45:00Z<![CDATA[Basel, February 05, 2024 – Novartis today announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (FSE: MOR; NASDAQ: MOR), a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. The acquisition, which is subject to customary closing conditions, including a minimum acceptance threshold of 65% of outstanding shares tendered in the takeover offer and regulatory approvals, further expands and complements Novartis pipeline in oncology, one of its priority therapeutic areas, while also enhancing Novartis global footprint in hematology.]]>https://www.globenewswire.com/news-release/2024/01/31/2820709/0/en/Novartis-delivers-strong-full-year-performance-10-net-sales-and-18-core-operating-income-growth-cc-with-margin-expansion-Continuing-innovation-momentum-with-multiple-positive-Ph3-r.html?f=22&fvtc=4&fvtv=30456Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts2024-01-31T06:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR]]>https://www.globenewswire.com/news-release/2024/01/31/2820709/0/fr/Novartis-forte-performance-en-2023-hausse-de-10-du-chiffre-d-affaires-net-et-de-18-du-r%C3%A9sultat-op%C3%A9rationnel-core-tcc-expansion-de-la-marge-Innovation-nombreux-r%C3%A9sultats-positifs-de.html?f=22&fvtc=4&fvtv=30456Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III2024-01-31T06:00:00Z<![CDATA[Annonce événementielle au sens de l’art. 53 RC]]>https://www.globenewswire.com/news-release/2024/01/31/2820709/0/de/Starkes-Jahresergebnis-Novartis-steigert-den-Nettoumsatz-um-10-das-operative-Kernergebnis-um-18-kWk-sowie-die-Margen-Weitere-Innovationsdynamik-mit-mehreren-positiven-Phase-3-Ergeb.html?f=22&fvtc=4&fvtv=30456Starkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen2024-01-31T06:00:00Z<![CDATA[Ad-hoc-Mitteilung gemäss Art. 53 KR ]]>https://www.globenewswire.com/news-release/2024/01/19/2812383/0/en/Novartis-Lutathera-significantly-reduced-risk-of-disease-progression-or-death-by-72-as-first-line-treatment-for-patients-with-advanced-gastroenteropancreatic-neuroendocrine-tumors.html?f=22&fvtc=4&fvtv=30456Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors2024-01-19T15:00:00Z<![CDATA[Basel, January 19, 2024 – Novartis today presented data from the Phase III NETTER-2 trial showing that Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus long-acting release (LAR) octreotide reduced the risk of disease progression or death by 72% as first-line therapy in patients with somatostatin receptor-positive (SSTR+) well-differentiated grade 2/3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus high-dose octreotide LAR alone1. Data were presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.]]>